Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 17
Figure 5. Europe AI in Drug Discovery Market, 2019-2026, $ mn 20
Figure 6. Primary Drivers and Impact Factors of Europe AI in Drug Discovery Market 22
Figure 7. Primary Restraints and Impact Factors of Europe AI in Drug Discovery Market 25
Figure 8. Investment Opportunity Analysis 29
Figure 9. Porter’s Fiver Forces Analysis of Europe AI in Drug Discovery Market 32
Figure 10. Breakdown of Europe AI in Drug Discovery Market by Offering, 2019-2026, % of Revenue 36
Figure 11. Contribution to Europe 2020-2026 Cumulative Revenue by Offering, Value ($ mn) and Share (%) 37
Figure 12. Europe AI in Drug Discovery Market: Software, 2015-2026, $ mn 38
Figure 13. Europe AI in Drug Discovery Market: Service, 2015-2026, $ mn 39
Figure 14. Breakdown of Europe AI in Drug Discovery Market by Technology, 2019-2026, % of Revenue 40
Figure 15. Contribution to Europe 2020-2026 Cumulative Revenue by Technology, Value ($ mn) and Share (%) 41
Figure 16. Europe AI in Drug Discovery Market: Deep Learning, 2015-2026, $ mn 42
Figure 17. Europe AI in Drug Discovery Market: Supervised Learning, 2015-2026, $ mn 43
Figure 18. Europe AI in Drug Discovery Market: Reinforcement Learning, 2015-2026, $ mn 44
Figure 19. Europe AI in Drug Discovery Market: Unsupervised Learning, 2015-2026, $ mn 45
Figure 20. Europe AI in Drug Discovery Market: Other Technologies, 2015-2026, $ mn 46
Figure 21. Breakdown of Europe AI in Drug Discovery Market by Drug Type, 2019-2026, % of Revenue 47
Figure 22. Contribution to Europe 2020-2026 Cumulative Revenue by Drug Type, Value ($ mn) and Share (%) 48
Figure 23. Europe AI in Drug Discovery Market: Large-molecule Drugs, 2015-2026, $ mn 49
Figure 24. Europe AI in Drug Discovery Market: Small-molecular Drugs, 2015-2026, $ mn 50
Figure 25. Breakdown of Europe AI in Drug Discovery Market by Therapeutic Area, 2019-2026, % of Revenue 51
Figure 26. Contribution to Europe 2020-2026 Cumulative Revenue by Therapeutic Area, Value ($ mn) and Share (%) 52
Figure 27. Europe AI in Drug Discovery Market: Oncology, 2015-2026, $ mn 54
Figure 28. Europe AI in Drug Discovery Market: Neurodegenerative Diseases, 2015-2026, $ mn 55
Figure 29. Europe AI in Drug Discovery Market: Cardiovascular Disease, 2015-2026, $ mn 56
Figure 30. Europe AI in Drug Discovery Market: Metabolic Diseases, 2015-2026, $ mn 57
Figure 31. Europe AI in Drug Discovery Market: Other Therapeutic Areas, 2015-2026, $ mn 58
Figure 32. Breakdown of Europe AI in Drug Discovery Market by Application, 2019-2026, % of Revenue 59
Figure 33. Contribution to Europe 2020-2026 Cumulative Revenue by Application, Value ($ mn) and Share (%) 60
Figure 34. Europe AI in Drug Discovery Market: Information & Data Analysis, 2015-2026, $ mn 61
Figure 35. Europe AI in Drug Discovery Market: Drug Design, 2015-2026, $ mn 62
Figure 36. Europe AI in Drug Discovery Market: Drug Evaluation, 2015-2026, $ mn 63
Figure 37. Europe AI in Drug Discovery Market: Clinical Trials, 2015-2026, $ mn 64
Figure 38. Europe AI in Drug Discovery Market: Other Applications, 2015-2026, $ mn 65
Figure 39. Breakdown of Europe AI in Drug Discovery Market by End User, 2019-2026, % of Revenue 66
Figure 40. Contribution to Europe 2020-2026 Cumulative Revenue by End User, Value ($ mn) and Share (%) 67
Figure 41. Europe AI in Drug Discovery Market: Pharmaceutical & Biotechnology Companies, 2015-2026, $ mn 68
Figure 42. Europe AI in Drug Discovery Market: Academic & Research Institutes, 2015-2026, $ mn 69
Figure 43. Europe AI in Drug Discovery Market: Contract Research Organizations, 2015-2026, $ mn 70
Figure 44. Breakdown of European AI in Drug Discovery Market by Country, 2019 and 2026, % of Revenue 72
Figure 45. Contribution to Europe 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 73
Figure 46. AI in Drug Discovery Market in UK, 2015-2026, $ mn 75
Figure 47. AI in Drug Discovery Market in France, 2015-2026, $ mn 77
Figure 48. AI in Drug Discovery Market in Germany, 2015-2026, $ mn 79
Figure 49. AI in Drug Discovery Market in Spain, 2015-2026, $ mn 81
Figure 50. AI in Drug Discovery Market in Italy, 2015-2026, $ mn 83
Figure 51. AI in Drug Discovery Market in Russia, 2015-2026, $ mn 85
Figure 52. AI in Drug Discovery Market in Rest of Europe, 2015-2026, $ mn 87
Figure 53. Growth Stage of Europe AI in Drug Discovery Industry over the Forecast Period 89
Figure 54. Share of Developments of Key Vendors by Strategy Type, 2015-2019 91
Europe artificial intelligence (AI) in drug discovery market reached $108.6 million in 2019 and will grow by 28.7% over 2020-2026 owing to the rising need for AI technology in drug discovery and development. Highlighted with 37 tables and 54 figures, this 123-page report “Europe Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe AI in drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country. Based on offering, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Software • Service Based on technology, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Deep Learning • Supervised Learning • Reinforcement Learning • Unsupervised Learning • Other Technologies Based on drug type, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Large-molecule Drugs • Small-molecular Drugs Based on therapeutic area, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Oncology • Neurodegenerative Diseases • Cardiovascular Disease • Metabolic Diseases • Other Therapeutic Areas Based on application, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Information & Data Analysis • Drug Design • Drug Evaluation • Clinical Trials • Other Applications Based on end user, the Europe market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section. • Pharmaceutical & Biotechnology Companies • Academic & Research Institutes • Contract Research Organizations Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each of the aforementioned countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Technology, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe AI in drug discovery market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Atomwise, Inc. BenevolentAI Berg LLC Bioage BIOAGE Cloud Pharmaceuticals, Inc. Cyclica Deep Genomics Envisagenics Exscientia Google IBM Corporation Insilico Medicine Microsoft Corporation Numedii, Inc. Numerate NVIDIA Corporation Owkin, Inc. Twoxar, Incorporated Verge Genomics Xtalpi, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More